TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.
EOS=eosinophils; IgE=immunoglobulin E.
However your practice chooses to access treatment, we’re here to help
From copay cards to coverage or appeals assistance, our TEZSPIRE Together program supports you and your patients throughout their treatment journey.
MAJORITY OF COMMERCIALLY INSURED PATIENTS HAVE ACCESS TO TEZSPIRE 1 *
The pre-filled pen is now covered* by 3 major pharmacy benefit managers. 1
CVS Caremark ®
Express-Scripts ®
OptumRx ®
Commercially eligible patients may pay $0 ‡ with the TEZSPIRE Together copay program
Covers up to $100 per month of the patient costs for in-office administration
Patients enrolled in the TEZSPIRE Together copay program are nearly 2x more likely to fill their TEZSPIRE prescription compared to those who do not enroll. 2
*The information provided herein is not a guarantee of coverage or payment (partial or full). Actual health benefits are determined by each plan administrator in accordance with its respective policy and procedures. Payer policies may vary. For the most up-to-date and complete information regarding the status of TEZSPIRE, please contact the payer directly.
†Coverage may vary based on local plan.
‡For eligible commercially insured patients only. Eligibility criteria and program maximums apply. See TEZSPIRETogether.com for full Terms and Conditions.
New expanded coverage for TEZSPIRE pen! 1,3
February 2023
~35% lives covered 3§||
June 2024
~89% lives covered 1§¶
Majority covered to label or better
Majority not covered/unknown
§Excludes health exchange and government plans (DoD, IHS, VA, and GEHA).
Assumptions: no biologic step-through requirements or no mention of EOS or IgE levels at baseline.1,3
||Based on MMIT data, February 2023.
¶Based on MMIT data, June 2024.
DoD=Department of Defense; EOS=eosinophils; GEHA=Government Employees Health Association;
IgE=immunoglobulin E; IHS=Indian Health Service; MMIT=Managed Markets Insight & Technology;
VA=Veterans Affairs.
THERE ARE TWO WAYS TO ACCESS TEZSPIRE
Buy and Bill
Specialty Pharmacy
Find authorized specialty distributors and specialty pharmacy providers where TEZSPIRE can be obtained.
Refer patients to alternate sites for administration or specialty pharmacy locations.
RESOURCES AVAILABLE THROUGHOUT YOUR PATIENTS’ TREATMENT JOURNEY
TEZSPIRE Together Copay Program*
Helps eligible commercially insured patients reduce out-of-pocket costs.
TEZSPIRE Together Fast Start Program*
Helps eligible commercially insured patients start on therapy quickly, even before submitting prior authorization paperwork.
Patient Portal
Empowers patients to take a more active role in their treatment journey.
Nurse Educators †
Help patients with questions about TEZSPIRE.
Enrolling is the first step in accessing the various support services offered by TEZSPIRE Together. There are 3 ways you can help your TEZSPIRE patients enroll:
HCP Portal Online
Register through the Healthcare Provider Portal
Fax
Fax the printed enrollment form to
1-888-388-6016
Call
Call TEZSPIRE Together at 1-888-TZSPIRE
(1-888-897-7473)
*For eligible commercially insured patients only. Eligibility criteria and program maximums apply. See TEZSPIRETogether.com for full Terms and Conditions.
†Nurse educators are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. Nurse educators do not inject patients with TEZSPIRE. Patients will be referred to their doctor’s office for clinical advice.
TEZSPIRE Together HCP Portal
Enrolling is the first step in accessing the various support services offered by TEZSPIRE Together. There are 3 ways you can help your TEZSPIRE patients enroll:
HCP Portal Online
Register through the Healthcare Provider Portal
Fax
Fax the printed enrollment form to
1-888-388-6016
Call
Call TEZSPIRE Together at 1-888-TZSPIRE
( 1-888-897-7473)
*For eligible commercial patients only. Eligibility criteria and program maximums apply. See TEZSPIRETogether.com for full Terms and Conditions.
For your uninsured or Medicare Part B patients without supplemental insurance, please call 1-888-TZSPIRE (1-888-897-7473) to speak with a live Support Specialist about the TEZSPIRE Patient Assistance Program and other financial assistance options.
Thank you for signing up.
Collapse
CONTRAINDICATIONS
Known hypersensitivity to tezepelumab-ekko or excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.
Acute Asthma Symptoms or Deteriorating Disease
TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
Abrupt Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
Live Attenuated Vaccines
The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.
USE IN SPECIFIC POPULATIONS
There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
INDICATION
TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.
Please see full Prescribing Information, including
Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products.
Opens new window
Collapse
CONTRAINDICATIONS
Known hypersensitivity to tezepelumab-ekko or excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.
Acute Asthma Symptoms or Deteriorating Disease
TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
Abrupt Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
Live Attenuated Vaccines
The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.
USE IN SPECIFIC POPULATIONS
There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
INDICATION
TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.
Please see full Prescribing Information, including
Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products.Opens new window
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.
Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
References: 1. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.
References: 1. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 2. Data on File. REF-US-100158, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-87321, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma [supplement]. N Engl J Med. 2021;384(19):1800-1809.
References: 1. Chipps BE, Soong W, Panettieri R Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 4. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 5. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 6. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.
References: 1. Data on File. REF- 134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Menzies-Gow A, Corren J, Israel E, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma and co-morbid nasal polyps in NAVIGATOR. Poster presented at: European Respiratory Society (ERS) International Congress; September 5-8, 2021; Sheffield, UK. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 8. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 9. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 10. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 6. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 7. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double- blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-148822, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 10. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 11. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 14. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 15. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 16. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 17. Data on File. US-100158, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.
Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
References: 1. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.
References: 1. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 2. Data on File. REF-US-100158, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-87321, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma [supplement]. N Engl J Med. 2021;384(19):1800-1809.
References: 1. Chipps BE, Soong W, Panettieri R Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 4. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 5. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 6. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.
References: 1. Data on File. REF- 134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Menzies-Gow A, Corren J, Israel E, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma and co-morbid nasal polyps in NAVIGATOR. Poster presented at: European Respiratory Society (ERS) International Congress; September 5-8, 2021; Sheffield, UK. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 8. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 9. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 10. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 6. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 7. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double- blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-148822, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 5. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; May 2023. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 10. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 11. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 14. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 15. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 16. Data on File. REF-91518, AstraZeneca Pharmaceuticals LP. 17. Data on File. US-100158, AstraZeneca Pharmaceuticals LP.
This product information is intended for US Healthcare Professionals only.
TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2024 AstraZeneca. All rights reserved. US-79076 Last Updated 10/24
